Is there an optimal time to measure quantitative HCV RNA to predict non- response following interferon treatment for chronic HCV infection?

Journal of Hepatology

Volumn 29, Issue 3, 1998, Pages 362-368

  McHutchison, John ^a   Blatt, Lawrence ^b   Sedghi Vaziri, Ali ^a   Russell, Jim ^b   Schmid, Peter ^b   Conrad, Andrew ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b National Genetics Institute   (United States)

Author keywords

HCV; Interferon; Prediction of non response; Serum HCV RNA

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; LYMPHOBLAST INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RNA ANALYSIS; VIRUS DETECTION; VIRUS TITRATION;

EID: 0032171326     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80052-4     Document Type: Article

References (27)

1. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med. 336:1997;347-356.
2. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B hepatitis: a meta-analysis of randomized clinical trials. J Hepatol. 13:1991;192-199.
3. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non A, non B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
4. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 101:1991;497-502.
5. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha2b. Hepatology. 18:1993;1300-1305.
6. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemmonier C, Trep C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
7. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.
8. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology. 106:1994;686-690.
9. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol. 21:1994;1-3.
10. Pol S, Jaffredo F, Nalpas B, Savada C, Berthelot P, Brechet C. Predictive value of HCV viremia after 3 months in the monitoring of antiviral treatments. [abstract] Hepatology. 20:1994;159.
11. Hino K, Okuda M, Konishi T, Ishioka H, Okita K. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alfa therapy. Dig Dis Sci. 40:1995;14-20.
12. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, et al. Loss of serum HCV RNA at week 4 of interferon alfa therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 46:1995;109-115.
13. Kohara M, Tanaka T, Tsukiyama-Kohara K, Tanaka S, Mizokami M, Lau JYN, et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-alfa with different virologic kinetics. J Infect Dis. 172:1995;934-938.
14. Kleter GEM, Brouwer JT, Heijtink RA, Schalm SW, Quint WGV. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother. 37:1993;595-597.
15. Hanely JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J, et al. Interferon treatment for chronic hepatitis C in hemophiliacs: influence of viral load, genotype, and liver pathology on response. Blood. 87:1996;1704-1709.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guaninidium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
17. Tong MJ, Blatt LM, McHutchison JG, Co Rl, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology. 26:1997;1640-1645.
18. Okamoto H, Okada S, Miyakawa Y, Mayumi M. The 5′ terminal sequence of the hepatitis C genome. Jpn J Exp Med. 60:1990;167-177.
19. Stuyver I, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol. 74:1993;1093-1102.
20. Friis Rh, Stellers TA. Epidemiology for Public Health Practice. 1996;Aspen Publications, Gaithersburg, Maryland.
21. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alpha and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology. 21:1995;1003-1010.
22. Castilla A, Prieto J, Fausto N. Transforming growth factors β1 and alpha in chronic liver disease. N Engl J Med. 324:1991;933-940.
23. Ziol M, Van Nhieu JT, Roudot-Thoroval F, Metreau JM, Deugnier Y, Dhumeaux D, et al. A histopathological study of the effects of 6-month versus 12-month interferon alpha 2b therapy in chronic hepatitis C. J Hepatol. 25:1996;833-841.
24. Jensen D, Shafritz D, Craig JR, Krawitt E. Nonresponders to CIFN show clinically relevant improvements in liver histology. [abstract] Gastroenterology. 112:1997;1294.
25. Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propetide of type III procollagen in patients with hepatitis C treated with interferon alfa. Hepatology. 22:1995;426-431.
26. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A. Relationship between biochemical, virological, and histological response during interferon treatment in chronic hepatitis C. Hepatology. 26:1997;780-785.
27. McHutchison JG, Blatt LM, Goodarzi K, Russell J, Conrad A. Ultracentrifugation and concentration of a large volume of serum for HCV RNA analysis during treatment may predict sustained and relapse in chronic HCV infection. [abstract] Gastroenterology. 112:1997;1330.